Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
Type:
Grant
Filed:
September 13, 2007
Date of Patent:
June 8, 2010
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
Abstract: The invention provides an amine salt of a carbostyril derivative formed from a carbostyril derivative represented by the formula (1) [wherein R is a halogen atom; the substituted position of the side chain is 3- or 4-position in the carbostyril skeleton; and the bonding between 3- and 4-positions of the carbostyril skeleton is a single bond or a double H bond] and an amine; and the invention is useful as drugs for treating various diseases, especially as aqueous formulations due to the superior water solubility and the superior pharmacologic effects.
Abstract: The present invention relates to compounds having a structure according to Formula I wherein n, m, z, R, R2, R3, R4, R5, R6, A, E, X, Y, a and b are as defined above; or an optical isomer, diastereomer or enantiomer thereof; a pharmaceutically acceptable salt, hydrate, or prodrug thereof.
Type:
Grant
Filed:
March 21, 2005
Date of Patent:
June 8, 2010
Assignee:
Janssen Pharmaceutica, N.V.
Inventors:
Eugene B. Grant, Mark J. Macielag, Steven David Paget, Michele Ann Weidner-Wells, Xiaoqing Xu, Xiaodong Xu
Abstract: 1-aryl-3,4-dihydro-1H-naphthalene-2-one is prepared by isomerizing an epoxy compound represented by the following general formula, wherein a is an integer of 0 to 5, b is an integer of 0 to 4, and R1 to R6 are hydrogen atoms or substituents such as alkyl groups, in an organic solvent in the presence of magnesium sulfate. This process makes it possible to prepare the 1-aryl-3,4-dihydro-1H-naphthalene-2-one safely and in a high yield without using highly explosive compounds such as lithium perchlorate.
Abstract: The present invention relates to compounds of formula I wherein R1, R2 and R3 are as defined in the specification, which are active at the GABAB receptor and which can be used for the treatment of CNS disorders.
Type:
Grant
Filed:
June 1, 2006
Date of Patent:
June 1, 2010
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Parichehr Malherbe, Raffaello Masciadri, Roger David Norcross, Eric Prinssen
Abstract: This invention relates to non-steroidal tricyclic compounds that are modulators of androgen receptors and to methods for making and using such compounds.
Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Type:
Grant
Filed:
October 7, 2005
Date of Patent:
June 1, 2010
Assignee:
Abbott Laboratories
Inventors:
Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
Abstract: There is described a process for the purification of an impure preparation containing fentanyl by means of a reverse phase preparative chromatography process. A chromatographic column is loaded with a stationary phase, typically a silica particle having an organic ligand bound thereto. With a loading ratio of from about 50 to about 150 the impure preparation is acidified and passed through the column. The column is eluted with typically an aqueous solution of acetonitrile and the purified fentanyl is obtained in a specified cut.
Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds of Formula (I). The invention also provides pharmaceutical compositions comprising such compounds, the use such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds. Wherein; R1 is hydrogen, halo, hadroxy, C1-4 alkyl, or C1-4 alkoxy; R2 is C3-4 alkyl, or C3-6cycloakyl; R3 is hydrogen or C1-3 alkyl: R4 is —S(O)2 R6 or —C(O)R7; R5 is hydrogen, C1-3alkyl, C2-3 alkyl substituted with —OH or C1-3 alkoxy, or —CH2-pyrydyl; R6 is C1-3 alkyl; or R5 and R6 taken together from C3-4 alkylenyl; and R7 is hydrogen, C1-3alkyl, or pyrydyl; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof.
Type:
Grant
Filed:
April 6, 2005
Date of Patent:
June 1, 2010
Assignee:
Theravance, Inc.
Inventors:
Daniel Marquess, Paul R. Fatheree, S. Derek Turner, Daniel D. Long
Abstract: The present invention provides a compound of the formula: Formula (I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, hypertension, and atherosclerosis, comprising administering to a patient in thereof an effective amount of a compound of Formula I.
Type:
Grant
Filed:
February 18, 2005
Date of Patent:
June 1, 2010
Assignee:
Eli Lilly and Company
Inventors:
Konstantinos Gavardinas, Prabhakar Kondaji Jadhav, Minmin Wang
Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.
Type:
Grant
Filed:
March 16, 2006
Date of Patent:
June 1, 2010
Assignee:
The Burnham Institute for Medical Research
Inventors:
Jeffrey W. Smith, Fumiko Axelrod, Steven J. Kridel, Daniel Romo, Vikram Purohit, Gil Ma
Abstract: Imidazo[1,2-a]pyridines of the formulae I and II: are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed.
Type:
Grant
Filed:
October 28, 2004
Date of Patent:
May 25, 2010
Assignee:
Sepracor, Inc.
Inventors:
Q. Kevin Fang, Paul Grover, Thomas P. Jerussi
Abstract: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.
Type:
Grant
Filed:
March 12, 2008
Date of Patent:
May 25, 2010
Assignee:
H. Lundbeck A/S
Inventors:
Robert Dancer, Hans Petersen, Ole Nielsen, Michael Harold Rock, Helle Eliasen, Ken Liljegren
Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an DPP4 modulated disease or disorder such as, for example, diabetes, by administration of a therapeutically effective dose of a compound according to Formula I. wherein X, Z, A, R2, Y, R1, n, and b are as defined herein.
Abstract: To provide a quinolone antibacterial drug and a therapeutic agent for infectious diseases, which exhibit potent antibacterial activity on Gram-positive and Gram-negative bacteria and which is highly safe. A compound represented by the following formula (1): (wherein R1 represents a C3-C6 cycloalkyl group which may have a substituent or the like; R2 represents a hydrogen atom or the like; R3 and R4 each independently represent a hydrogen atom or a C1-C6 alkyl group, or a substituted carboxyl group derived from an amino acid, a dipeptide, or a tripeptide, and, in the case where each of R3 and R4 represents a C1-C6 alkyl group, the alkyl group may be substituted by one or more atoms or groups selected from among a hydroxyl group, a halogen atom, a C1-C6 alkylthio group, and a C1-C6 alkoxy group; and n denotes an integer of 1 to 3), a salt thereof, and a hydrate of the compound or the salt. Also, antibacterial drugs and therapeutic agents for infectious diseases are prepared.
Abstract: Compounds of a certain formula (I) in which Ra and Rb have the meanings indicated in the description, are novel, effective compounds with anti-proliferative and/or apoptosis inducing activity.
Type:
Grant
Filed:
May 25, 2005
Date of Patent:
May 25, 2010
Assignee:
4SC AG
Inventors:
Klaus Pekari, Thomas Baer, Björn Bartels, Mathias Schmidt, Thomas Beckers
Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
Type:
Grant
Filed:
June 17, 2004
Date of Patent:
May 18, 2010
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Markus Boehringer, Bernd Kuhn, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Hans Peter Wessel
Abstract: Methods of using certain ?-aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.